Filters
CAR-T cell therapy is one of the newest and most promising treatments available for blood cancer. These treatments aid in the battle against cancer by utilizing your body's immune system.
Factors affecting the cost of CAR-T:
- Development and Manufacturing Costs: The scientific manipulation of a patient's T-cells to generate chimeric antigen receptors that specifically target cancer cells is the basis for CAR-T treatment. CAR-T cell development and production are intricate and costly processes requiring specialized laboratory equipment and methods. The total cost of CAR-T therapy is greatly increased by these up-front expenses.
- Type of Cancer: Certain cancers, including some forms of leukemia and lymphoma, have been approved for treatment with CAR-T therapy. The cost of CAR-T therapy and the intricacy of the treatment regimen may vary depending on the particular form of cancer being treated.
- Development and Manufacturing Costs: The scientific manipulation of a patient's T-cells to generate chimeric antigen receptors that specifically target cancer cells is the basis for CAR-T treatment. CAR-T cell development and production are intricate and costly processes requiring specialized laboratory equipment and methods. The total cost of CAR-T therapy is greatly increased by these up-front expenses.
- Type of Cancer: Certain cancers, including some forms of leukemia and lymphoma, have been approved for treatment with CAR-T therapy. The cost of CAR-T therapy and the intricacy of the treatment regimen may vary depending on the particular form of cancer being treated.
- Post-treatment Monitoring and Support: After receiving CAR-T therapy, patients need to be closely watched for any adverse effects, such as neurotoxicity and cytokine release syndrome (CRS), and their response to treatment needs to be continuously assessed. The total cost of treatment should account for the expenses of supportive care, side effect control, and monitoring following treatment.
- Geographic Location: The cost of healthcare varies by nation and location. Healthcare expenditures, even those for cutting-edge treatments like CAR-T therapy, are typically higher in urban areas or in locations with higher cost of living.
- Supply and Demand Dynamics: CAR-T therapy availability may be restricted in some areas, and treatment costs may be impacted by supply and demand dynamics. The possibility exists that treatment prices could go down over time as more facilities start to provide CAR-T therapy and as manufacturing procedures become more efficient.
| Country | Cost | Local_currency |
|---|---|---|
| United Kingdom | USD 373000 | 294670 |
| Turkey | USD 443200 | 13358048 |
| Spain | USD 375000 | 345000 |
| United States | USD 289550 | 289550 |
| Singapore | USD 251388 | 336860 |
CAR T-cell therapy represents a groundbreaking approach to harnessing the power of the body's immune system to combat cancer. By modifying T cells, a subset of white blood cells, in a laboratory setting, these cells are empowered to recognize and eliminate cancer cells with precision. Often categorized as a form of cell-based gene therapy, CAR T-cell therapy involves altering the genetic makeup of T cells, equipping them with the ability to target specific cancer antigens.
This innovative treatment has demonstrated remarkable efficacy, particularly in cases where conventional therapies have proven ineffective. Its ability to reprogram the immune system to target and destroy cancer cells marks a significant advancement in cancer treatment strategies.
Classification:
CAR T cell therapy is classified as follows:
- Structure-based classification:
- First-generation CAR T-cells: These CAR T-cells typically consist of an antigen-binding domain (single-chain variable fragment, scFv) linked to a T-cell activation domain, such as the CD3ζ chain. They lack additional co-stimulatory domains.
- Second-generation CAR T-cells: These CAR T-cells include an additional co-stimulatory domain, such as CD28 or 4-1BB (CD137), along with the CD3ζ chain. The presence of co-stimulatory domains enhances T-cell activation and persistence.
- Third-generation CAR T-cells: These CAR T-cells incorporate two co-stimulatory domains along with the CD3ζ chain, aiming to further enhance T-cell function and anti-tumor activity.
Antigen-based classification: It includes
- CD19-targeted CAR T-cells: CD19 is a common target for CAR T-cell therapy and is used in the treatment of B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of lymphoma.
- Other antigen-targeted CAR T-cells: CAR T-cells can be engineered to target a variety of antigens expressed on cancer cells, including but not limited to BCMA (B-cell maturation antigen), CD22, CD30, and EGFRvIII.
CAR T-cell therapy is primarily used to treat blood cancers, such as multiple myeloma, large B-cell lymphoma, and B-cell acute lymphoblastic leukaemia. The patient's own T cells are reprogrammed to identify and destroy cancer cells, cause remission, enhance survival, and have a plan B in case other treatments fail.
Patients with blood cancers who relapsed or are refractory must consult an oncologist to determine candidacy for CAR T therapy, especially if they have failed to respond to traditional treatments (i.e., chemotherapy, radiation, or stem cell transplant). Evaluation is warranted for symptoms such as loss of weight, swelling of lymph nodes, recurrent infection, chronic fatigue, or spontaneous bruising.
Screening tests consist of imaging, bone marrow biopsy, and blood work.Leukapheresis is utilised to harvest T cells from the patient's blood for T-cell collection.Bridging therapy: Certain patients receive chemotherapy while waiting for CAR T cells to be produced.Lymphodepleting chemotherapy is administered before the injection to make room for CAR T cells. The patients should plan for potential hospitalisation, designate caretakers, and discuss long-term follow-up and expected adverse effects with the medical team.
- T-cell harvesting: T cells are removed from the patient's blood by processing.
- Genetic alteration: T cells are designed in the laboratory to express CAR proteins targeting cancer cells.
- Expansion: Modified T cells are expanded to therapeutic levels.
- Infusion: Patient receives an intravenous infusion of CAR T cells.
- Monitoring: Intensive monitoring, often in the hospital, for side effects and reactions.
The whole process, from cell harvesting to infusion, can take three to six weeks. The infusion itself takes a few hours to a few minutes, but for at least one week following the infusion, close monitoring is required, and there will be frequent follow-ups for several months.
- Cytokine Release Syndrome (CRS)
- Neurotoxicity
- Infections
- Low blood counts
- Relapse or non-response
One of the newer treatment options for some blood cancers is CAR T-cell therapy. It is utilised when other treatments are not working or the cancer recurs. CAR T-cell therapy has the potential to cure many blood cancers and extend life in most cases.
Recovery involves managing side effects like CRS and neurotoxicity, monitoring blood levels, and avoiding infections. Laboratory testing, imaging, and monitoring for late issues like hypogammaglobulinemia or relapse are all included in long-term follow-up.
The nature of the cancer, the burden of the disease, and an individual's response all impact success. For example, in pediatric acute lymphoblastic leukaemia, complete remission rates are more than 80%. However, relapse is always a risk, and long-term success is variable.
Would you like some help? We are available.
Get Help Explore Hospitals ( 77 )
IRCCS Ospedale Galeazzi- Sant’Ambrogio
milan, Italy
- IRCCS Galeazzi Hospital – Sant’Ambrogio is a leading multidisciplinary hospital located in Milan, Italy. It is internationally renowned for its excellence in orthopaedics, cardiovascular care, and advanced minimally invasive surgery. The hospital features cutting-edge diagnostic technology and state-of-the-art surgical facilities. It is part of the San Donato Hospital Group, combining research, innovation, and high-quality patient care.
- Recognised since 2006 as an IRCCS for research in locomotor system diseases.
- It combines high‑quality clinical care with translational and basic research in orthopaedics, biomechanics, regenerative medicine, etc.
Marengo Asia Hospitals, Faridabad
Faridabad, India
Marengo Asia Hospitals, located in Faridabad, is a multispecialty, state-of-the-art, and patient-friendly facility that combines the greatest services available in the healthcare segment. With 325 beds now, the hospital can accommodate up to 550 beds. It has first-rate medical facilities including a Critical Care Medicine department for patients with life-threatening conditions. Furthermore, our highly skilled medical staff and cutting-edge software system make us the perfect facility for patients from various backgrounds. We always aim to exceed expectations and are always looking for ways to boost our performance.
Beijing GoBroad Boren Hospital
Beijing, China
- Beijing GoBroad Boren Hospital, part of GoBroad Medical (Haematology) Beijing Research Centre, is a leading centre for hematologic oncology, Parkinson’s disease, and liver cancer.
- The hospital spans 14,000 sq. meters and features 19 laminar flow wards, advanced operating rooms, and emergency facilities.
- Equipped with Siemens 64-slice CT and 3.0T MRI machines, along with specialised labs for cytology, flow cytometry, FISH, genetic analysis, virology, and pharmacology.
- Engages international experts and experienced physicians with over 30 years of clinical and laboratory expertise.
- Offers integrated and personalised treatments, including chemotherapy, radiotherapy, immunotherapy, targeted therapy, and demethylation therapy.
- Renowned for CAR-T therapy for refractory and relapsed leukaemia, lymphoma, and myeloma.
- Experienced in hematopoietic stem cell transplants for adults and children, including haploidentical, autologous, allogeneic, and salvage transplants, with success rates at international standards.
- Combines clinical care, advanced diagnostics, and research to deliver innovative treatments and improved outcomes for patients with complex hematologic diseases.
GoBroad Shanghai Zhaxin Hospital and Shanghai Liquan Hospital
Shanghai, China
- According to the GoBroad Medical Institute of Haematology (Shanghai Centre), Shanghai Zhaxin Hospital/Shanghai Liquan Hospital are specialised facilities dedicated to the advanced diagnosis and treatment of haematological disorders.
- The hospital is a member of the Shanghai Ruijin Hospital Blood Disease Medical Association and a licensed bone marrow transplant facility in China.
- It provides comprehensive care for complex and resistant blood illnesses, with more than 300 beds and state-of-the-art laminar airflow transplant wards.
- The facility, which is run by senior haematology specialists, is renowned for its individualised treatment plans, stem cell transplants, and precision diagnostics.
GoBroad Healthcare (Hematology) Guangdong Research Center
Dongguan, China
- GoBroad Healthcare (Haematology) Guangdong Research Centre is a leading haematology and paediatric transplant institute in China, led by Prof. Li Chunfu and in partnership with Mayo Clinic.
- Operating at Dongguan Taixin Hospital, the centre specialises in advanced diagnosis and treatment of blood and immune disorders, including thalassemia and leukaemia.
- With 1,186 transplants performed and a 97.6% survival rate in thalassemia, it is one of the world’s largest pediatric hematopoietic stem cell transplant centres.
Marengo Asia Hospitals, Gurugram
Gurgaon, India
- Marengo Asia Hospitals, Gurugram, is a 250-bed multi-speciality tertiary care hospital, formerly known as W Pratiksha Hospital.
- A major medical centre for Delhi NCR and North India, it is situated on Golf Course Extension Road, Sector 56, Gurugram.
- The hospital's NABH and NABL accreditation ensures compliance with international standards for patient care, safety, and quality.
- Provides extensive medical care in more than 21 specialities, including as women's health, neurology, orthopaedics, cardiology, and cancer.
- Advanced robotic-assisted spine surgery tools and neuro-monitoring technology are available at the Marengo Asia International Institute of Neuro & Spine (MAIINS), a Centre of Excellence in Neurosciences.
- Equipped with cutting-edge equipment, such as automated labs, sophisticated imaging, and contemporary operating rooms.
- Features specialised ICUs, NICUs, and modular OTs built for complex and minimally invasive procedures.
Beijing GoBroad Hospital
Beijing, China
- Beijing GoBroad Hospital is an international, research-driven hospital focused on the diagnosis and treatment of complex and critical diseases, with a strong emphasis on clinical research and translational medicine.
- Recognised as a key public clinical research platform in Beijing, it is part of the city’s strategic “3 ? 100” priority projects.
- Located in Zhongguancun (Changping) Life Science Park, the hospital integrates clinical care, research, and industry to support medical innovation.
- Opened in July 2023, the hospital spans nearly 100,000 square meters and has a planned capacity of 500 beds, including dedicated early-phase clinical research beds.
- It specialises in solid tumors, hematologic malignancies, and neurosciences, offering advanced care for complex and refractory conditions.
- As the flagship hospital of GoBroad Healthcare Group, it combines expert-led care with advanced research infrastructure to deliver innovative treatment options and improved outcomes for patients with life-threatening illnesses.
Need Some Advice From Our Experts?
Request a Call Back Now!
Our team of healthcare experts would be happy to assist you
+99Process Involved for CAR-T
- Preoperative Stage: An assessment of the patient's medical history, including testing to determine eligibility for CAR-T therapy and identify the target antigen on cancer cells.
- Treatment Plan Discussion: An oncologist discusses the procedure of CAR-T therapy, including potential dangers, advantages, and side effects.
- Therapeutic Stage: T-cells are extracted from the patient, modified in the lab to express a chimeric antigen receptor (CAR), and reintroduced into the patient to target and destroy cancer cells.
- Postoperative Phase: Closely monitor for side effects. Follow-ups are scheduled regularly to check the response and treat any complications.
- Cancer patients, especially those suffering from blood cancers like leukemia, lymphoma, and multiple myeloma.
- Patients who have not responded to previous therapies, such as chemotherapy or radiation.
- Patients in good overall health with a functioning immune system.
- Individuals who have specific genetic markers that qualify them for CAR-T treatment.
- Targeted Action: CAR-T treatment specifically targets cancer cells, increasing efficacy while minimising damage to healthy cells.
- Potential for Remission: Can result in long-term remission, even in people with difficult-to-treat cancer.
- Minimally Invasive: The treatment consists mainly of an outpatient procedure for T-cell collection, with the therapy provided via infusion.
- Fill out the inquiry form: Fill out the form to provide us with the relevant information about your condition.
- Consult with Our Healthcare Expert: One of our qualified specialists will contact you for a consultation.
- Receive a Detailed Treatment Plan: After examining your situation, we will provide you with a detailed treatment plan that includes expert views and cost breakdowns for various choices.
- Choose your preferred option: Choose the treatment option that suits you the best.
